Estianeptine
 | |
| Clinical data | |
|---|---|
| Other names | (S)-Tianeptine; S-Tianeptine; TNX-4300; TNX4300 |
| Routes of administration | Oral[1] |
| Drug class | Peroxisome proliferator-activated receptor (PPAR) agonist; PPARβ/δ and PPARγ agonist |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H25ClN2O4S |
| Molar mass | 436.95 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estianeptine, also known as (S)-tianeptine and by its developmental code name TNX-4300, is a peroxisome proliferator-activated receptor (PPAR) agonist and atypical tricyclic antidepressant (TCA) which is under development for the treatment of Alzheimer's disease, bipolar disorders, major depressive disorder, and Parkinson's disease.[1][2][3][4][5] It is taken orally.[1]
Pharmacology
[edit]The drug is the (S)- enantiomer of the atypical TCA and weak opioid tianeptine.[1][4][5][6] It acts as a selective PPARβ/δ and PPARγ agonist.[1][2][4][7] The drug has been found to promote neuroplasticity in vitro, which is thought to be mediated by its PPAR agonism.[4][7] In addition, it has been found to improve cognition and memory in rodents.[8][9] In contrast to tianeptine and (R)-tianeptine, estianeptine shows no activity as a μ-opioid receptor (MOR) agonist.[1][4][7] Moreover, unlike estianeptine, (R)-tianeptine has no activity as a PPAR agonist.[4][7] It has been proposed that estianeptine, via its PPAR agonism, is responsible for the antidepressant effects of tianeptine, rather than tianeptine's weak MOR agonism that manifests at high doses being responsible.[4][7][10] Tianeptine's PPAR agonism may also be responsible for the drug's anti-inflammatory effects.[7]
History
[edit]Estianeptine was first described in the scientific literature by 1997.[11] It is being developed by Tonix Pharmaceuticals.[1][2][4] As of August 2023, the drug is in the preclinical research stage of development for all indications.[1][2] Tianeptine's PPAR agonism was first described in 2022.[12]
See also
[edit]References
[edit]- 1 2 3 4 5 6 7 8 "Estianeptine - Tonix Pharmaceuticals Holding Corp - AdisInsight". adisinsight.springer.com. Retrieved 4 August 2026.
- 1 2 3 4 "Delving into the Latest Updates on Estianeptine with Synapse". Synapse. 8 May 2025. Retrieved 4 August 2026.
- ↑ "Estianeptine Drug Profile". Ozmosi. 1 January 1900. Retrieved 4 August 2026.
- 1 2 3 4 5 6 7 8 Sullivan GM, Daugherty BL, Hsu DT, Rideout DC, Bavari S, Cho J, et al. (8 November 2023). Proposed Mechanism of Tianeptine, a Plastogen Antidepressant in Phase II Development in the United States (PDF). CNS Summit 2023. Vol. 20. Boston, Massachusetts, US: Innovations in Clinical Neuroscience. pp. S23–S23. PMC 10712291. Retrieved 4 August 2026.
- 1 2 Aslani S, Nafie J, Wahab MF, Armstrong DW (November 2025). "Tianeptine: enantiomeric separations, structural assignment, and biological interactions". Talanta. 294 128197. doi:10.1016/j.talanta.2025.128197. PMID 40339337.
- ↑ Nishio Y, Lindsley CW, Bender AM (November 2024). "Classics in Chemical Neuroscience: Tianeptine". ACS Chemical Neuroscience. 15 (21): 3863–3873. doi:10.1021/acschemneuro.4c00519. PMC 11587517. PMID 39382192.
- 1 2 3 4 5 6 Sullivan GM, Peters A, Hsu D, Rideout D, Roush T, Daugherty B, et al. (1 June 2023). A Randomized Placebo-Controlled Multicenter Trial of Monotherapy with TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for Treatment of Major Depressive Disorder (MDD) (PDF). American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting. Miami, Florida.
- ↑ BioWorld (25 July 2023). "Rat NOR test results support memory- and cognition-enhancing effects of estianeptine". BioWorld. Retrieved 4 August 2026.
- ↑ "Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test". Tonix Pharmaceuticals Holding Corp. 24 July 2023. Retrieved 4 August 2026.
- ↑ "Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression". Tonix Pharmaceuticals Holding Corp. 17 May 2023. Retrieved 4 August 2026.
- ↑ Oluyomi AO, Datla KP, Curzon G (March 1997). "Effects of the (+) and (-) enantiomers of the antidepressant drug tianeptine on 5-HTP-induced behaviour". Neuropharmacology. 36 (3): 383–387. doi:10.1016/s0028-3908(97)00016-6. PMID 9175617.
- ↑ Helmstädter M, Schierle S, Isigkeit L, Proschak E, Marschner JA, Merk D (September 2022). "Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists". International Journal of Molecular Sciences. 23 (17). doi:10.3390/ijms231710070. PMC 9456086. PMID 36077469.
Table 1. In vitro activity of FAMs with possibly relevant side-target activity and with potential for SOSA1. [...] Tianeptine: [...] partial PPARδ agonist EC50 = 28 ± 4 µM (43 ± 4% max. act.)